| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | 0.081 | 0.02 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | 0.085 | 0.02 |
| mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | 0.078 | 0.02 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | -0.084 | 0.02 |
| mRNA | FGIN-1-27 | CTRPv2 | pan-cancer | AAC | -0.17 | 0.02 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.075 | 0.02 |
| mRNA | BMS-345541 | CTRPv2 | pan-cancer | AAC | 0.085 | 0.02 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.088 | 0.02 |
| mRNA | niclosamide | CTRPv2 | pan-cancer | AAC | 0.083 | 0.02 |
| mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | 0.079 | 0.02 |